Pub Date : 2023-01-01DOI: 10.5005/jp-journals-10018-1368
Tarana Gupta
Acute hepatitis in patients on chemotherapy has always been challenging. Demystifying the truth becomes essential to continue chemotherapy. Wepresent a case of carcinoma buccal mucosa who developed acute hepatitis following a single dose of cisplatin and radiotherapy. In the background of a history of chronic alcoholism, and alcohol abstinence of more than 3 months, acute alcoholic hepatitis was unlikely. Though he had occult hepatitis B with HBsAg negative and positive IgG anti-HBc antibody status, however, with undetectable HBV DNA PCR quantitative, hepatitis B was unlikely to be the cause of acute hepatitis. With all viral markers including atypical viruses and autoimmune work-up being negative, it was a real-time challenge to find the exact cause.
How to cite this article: Gupta T. Acute Hepatitis in an Immunosuppressed Patient: A Dilemma. Euroasian J Hepato-Gastroenterol 2023;13(1):26-27.
接受化疗的急性肝炎患者一直具有挑战性。揭开真相对继续化疗至关重要。我们报告一例颊粘膜癌患者在单剂量顺铂和放疗后发生急性肝炎。在有慢性酒精中毒史且戒酒超过3个月的背景下,不太可能出现急性酒精性肝炎。尽管他患有隐匿性乙型肝炎,HBsAg阴性,IgG抗-HBc抗体阳性,但由于HBV DNA PCR定量检测不到,乙型肝炎不太可能是急性肝炎的原因。由于包括非典型病毒和自身免疫检查在内的所有病毒标志物都是阴性的,寻找确切原因是一项实时挑战。如何引用这篇文章:Gupta T.免疫抑制患者的急性肝炎:一个困境。Euroasian J Hepato-Gastroenterol 2023;13(1):26-27。
{"title":"Acute Hepatitis in an Immunosuppressed Patient: A Dilemma.","authors":"Tarana Gupta","doi":"10.5005/jp-journals-10018-1368","DOIUrl":"10.5005/jp-journals-10018-1368","url":null,"abstract":"<p><p>Acute hepatitis in patients on chemotherapy has always been challenging. Demystifying the truth becomes essential to continue chemotherapy. Wepresent a case of carcinoma buccal mucosa who developed acute hepatitis following a single dose of cisplatin and radiotherapy. In the background of a history of chronic alcoholism, and alcohol abstinence of more than 3 months, acute alcoholic hepatitis was unlikely. Though he had occult hepatitis B with HBsAg negative and positive IgG anti-HBc antibody status, however, with undetectable HBV DNA PCR quantitative, hepatitis B was unlikely to be the cause of acute hepatitis. With all viral markers including atypical viruses and autoimmune work-up being negative, it was a real-time challenge to find the exact cause.</p><p><strong>How to cite this article: </strong>Gupta T. Acute Hepatitis in an Immunosuppressed Patient: A Dilemma. Euroasian J Hepato-Gastroenterol 2023;13(1):26-27.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"13 1","pages":"26-27"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/21/ejohg-13-26.PMC10405803.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10319599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.5005/jp-journals-10018-1387
Tuğba Ocak, Macit Gülten
Abstract Background Spontaneous bacterial peritonitis (SBP) is an important reason for mortality in cirrhosis. This study aimed to identify the factors associated with mortality in SBP. Materials and methods A total of 69 patients with cirrhosis and 74 with SBP attacks that occurred in this group were assessed. Demographic data, symptoms at admission, comorbidities, laboratory parameters, treatment protocols, causes of cirrhosis, scoring characteristics, cirrhosis complications, and mortality were analyzed. Results Model for end-stage liver disease (MELD; p = 0.001), sodium-MELD (p = 0.001), and Child–Pugh–Turcotte (CTP) (p < 0.001) scores were correlated with mortality in patients with SBP episodes. Hepatorenal syndrome (p = 0.001) and esophageal variceal bleeding (p < 0.001) related to mortality. Serum lactate dehydrogenase (LDH) (p = 0.007), serum leukocyte (p = 0.017), and serum hemoglobin (p = 0.010) values had a statistically significant effect on mortality in multivariate regression analysis. Discussion The mortality rate can be reduced by identifying factors influencing death in patients with SBP episodes. How to cite this article Ocak T, Gülten M. Retrospective Investigation of Factors Affecting Mortality in Spontaneous Bacterial Peritonitis. Euroasian J Hepato-Gastroenterol 2023;13(1):5–9.
{"title":"Retrospective Investigation of Factors Affecting Mortality in Spontaneous Bacterial Peritonitis.","authors":"Tuğba Ocak, Macit Gülten","doi":"10.5005/jp-journals-10018-1387","DOIUrl":"10.5005/jp-journals-10018-1387","url":null,"abstract":"Abstract Background Spontaneous bacterial peritonitis (SBP) is an important reason for mortality in cirrhosis. This study aimed to identify the factors associated with mortality in SBP. Materials and methods A total of 69 patients with cirrhosis and 74 with SBP attacks that occurred in this group were assessed. Demographic data, symptoms at admission, comorbidities, laboratory parameters, treatment protocols, causes of cirrhosis, scoring characteristics, cirrhosis complications, and mortality were analyzed. Results Model for end-stage liver disease (MELD; p = 0.001), sodium-MELD (p = 0.001), and Child–Pugh–Turcotte (CTP) (p < 0.001) scores were correlated with mortality in patients with SBP episodes. Hepatorenal syndrome (p = 0.001) and esophageal variceal bleeding (p < 0.001) related to mortality. Serum lactate dehydrogenase (LDH) (p = 0.007), serum leukocyte (p = 0.017), and serum hemoglobin (p = 0.010) values had a statistically significant effect on mortality in multivariate regression analysis. Discussion The mortality rate can be reduced by identifying factors influencing death in patients with SBP episodes. How to cite this article Ocak T, Gülten M. Retrospective Investigation of Factors Affecting Mortality in Spontaneous Bacterial Peritonitis. Euroasian J Hepato-Gastroenterol 2023;13(1):5–9.","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"13 1","pages":"5-9"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/20/58/ejohg-13-5.PMC10405801.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.5005/jp-journals-10018-1358
Vincent Zimmer
How to cite this article: Zimmer V. The Hooking Technique for Retrograde Freehand Access during Direct Cholangioscopy (with Video). Euroasian J Hepato-Gastroenterol 2023;13(1):40.
{"title":"The Hooking Technique for Retrograde Freehand Access during Direct Cholangioscopy (with Video).","authors":"Vincent Zimmer","doi":"10.5005/jp-journals-10018-1358","DOIUrl":"10.5005/jp-journals-10018-1358","url":null,"abstract":"<p><p><b>How to cite this article</b>: Zimmer V. The Hooking Technique for Retrograde Freehand Access during Direct Cholangioscopy (with Video). Euroasian J Hepato-Gastroenterol 2023;13(1):40.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"13 1","pages":"40"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/a7/ejohg-13-40.PMC10405810.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9965733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Killian-Jamieson diverticulum (KJD) is a rare esophageal diverticulum that arises from the anterolateral wall of the proximal cervical esophagus in the Killian-Jamieson space. Although rare presentations include dysphagia, globus sensation, or a suspected thyroid nodule, it is often asymptomatic. Treatment is indicated only in symptomatic cases. We report a 55-year-old female who had long-standing heartburn and presents now with dysphagia, weight loss, and anemia. Imaging and upper endoscopy revealed peptic stricture and an associated KJD. She underwent serial endoscopic dilatation of the peptic stricture and was symptomatically better afterwards. She is currently doing well on follow-up.
How to cite this article: Sirasapalli SK, Senthamizhselvan K, Mohan P. Rare Association of Killian-Jamieson Diverticulum and Peptic Stricture of the Esophagus: Is It Causal or Casual? Euroasian J Hepato-Gastroenterol 2023;13(1):32-35.
{"title":"Rare Association of Killian-Jamieson Diverticulum and Peptic Stricture of the Esophagus: Is It Causal or Casual?","authors":"Siva Krishna Sirasapalli, Kuppusamy Senthamizhselvan, Pazhanivel Mohan","doi":"10.5005/jp-journals-10018-1388","DOIUrl":"10.5005/jp-journals-10018-1388","url":null,"abstract":"<p><p>Killian-Jamieson diverticulum (KJD) is a rare esophageal diverticulum that arises from the anterolateral wall of the proximal cervical esophagus in the Killian-Jamieson space. Although rare presentations include dysphagia, globus sensation, or a suspected thyroid nodule, it is often asymptomatic. Treatment is indicated only in symptomatic cases. We report a 55-year-old female who had long-standing heartburn and presents now with dysphagia, weight loss, and anemia. Imaging and upper endoscopy revealed peptic stricture and an associated KJD. She underwent serial endoscopic dilatation of the peptic stricture and was symptomatically better afterwards. She is currently doing well on follow-up.</p><p><strong>How to cite this article: </strong>Sirasapalli SK, Senthamizhselvan K, Mohan P. Rare Association of Killian-Jamieson Diverticulum and Peptic Stricture of the Esophagus: Is It Causal or Casual? Euroasian J Hepato-Gastroenterol 2023;13(1):32-35.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"13 1","pages":"32-35"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/d9/ejohg-13-32.PMC10405809.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10019954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The incidence of nonalcoholic fatty liver disease (NAFLD) has seen a steep rise in parallel with the global obesity and metabolic syndrome epidemic. The presence of NAFLD contributes to significant socioeconomic burden due to healthcare costs, progression of liver disease as non-alcoholic steatohepatitis (NASH), and later cirrhosis and hepatocellular carcinoma (HCC). With the advent of widely available imaging, it is also being detected as an incidental diagnosis in individuals with systemic disease like metabolic syndrome, diabetes, chronic cardiac disease, polycystic ovarian syndrome, etc. or in asymptomatic persons on presurgical evaluation or even annual health assessments. Gastroenterologists, hepatologists, physicians and surgeons need to be updated about the new diagnostic criteria of Metabolic (dysfunction)-associated fatty liver disease, noninvasive tests (NITs) of liver fibrosis, new tools of elastography, and identification of those with high-risk disease. In this review, we appraise the relevance of new diagnostic definitions, steatosis and fibrosis estimation tests, advanced imaging like magnetic resonance elastography and proton density fat fraction and discuss the diagnostic algorithm for incidentally detected NAFLD.
How to cite this article: Mishra S, Bhujade H, Butt AS, et al. Work-up for Incidentally Detected NAFLD: How Far is It Worth? Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S26-S36.
{"title":"Work-up for Incidentally Detected NAFLD: How Far is It Worth?","authors":"Saurabh Mishra, Harish Bhujade, Amna Subhan Butt, Lubna Kamani, Madhumita Premkumar","doi":"10.5005/jp-journals-10018-1364","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1364","url":null,"abstract":"<p><p>The incidence of nonalcoholic fatty liver disease (NAFLD) has seen a steep rise in parallel with the global obesity and metabolic syndrome epidemic. The presence of NAFLD contributes to significant socioeconomic burden due to healthcare costs, progression of liver disease as non-alcoholic steatohepatitis (NASH), and later cirrhosis and hepatocellular carcinoma (HCC). With the advent of widely available imaging, it is also being detected as an incidental diagnosis in individuals with systemic disease like metabolic syndrome, diabetes, chronic cardiac disease, polycystic ovarian syndrome, etc. or in asymptomatic persons on presurgical evaluation or even annual health assessments. Gastroenterologists, hepatologists, physicians and surgeons need to be updated about the new diagnostic criteria of Metabolic (dysfunction)-associated fatty liver disease, noninvasive tests (NITs) of liver fibrosis, new tools of elastography, and identification of those with high-risk disease. In this review, we appraise the relevance of new diagnostic definitions, steatosis and fibrosis estimation tests, advanced imaging like magnetic resonance elastography and proton density fat fraction and discuss the diagnostic algorithm for incidentally detected NAFLD.</p><p><strong>How to cite this article: </strong>Mishra S, Bhujade H, Butt AS, <i>et al</i>. Work-up for Incidentally Detected NAFLD: How Far is It Worth? Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S26-S36.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"12 Suppl 1","pages":"S26-S36"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/e7/ejohg-12-s26.PMC9681574.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35344076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.5005/jp-journals-10018-1361
Ben L Da, Jinendra Satiya, Rajiv P Heda, Yu Jiang, Lawrence F Lau, Ahmed Fahmy, Aaron Winnick, Nitzan Roth, Elliot Grodstein, Paul J Thuluvath, Ashwani K Singal, Thomas D Schiano, Lewis W Teperman, Sanjaya K Satapathy
Background: Graft macrosteatosis can predispose to a higher risk of graft loss so we sought to redefine acceptable cutoffs for graft steatosis.
Methods: Data of 26,103 donors who underwent liver transplantation (LT) between January 2004 and December 2018 from the UNOS-STAR database were utilized. A high-risk steatotic (HRS) graft and a low-risk steatotic (LRS) graft were defined as ≥20% and <20% macrosteatosis, respectively. High-risk steatotic grafts were further classified as grafts with 20-29% (G1S grafts), 30-39% (G2S grafts), and ≥40% steatosis (G3S grafts). Outcomes between groups were compared.
Results: LRS grafts had excellent graft (93.3 and 87.7%) and overall survival (95.4 and 90.5%) at 90 days and 1 year. Compared to LRS grafts, G1S, G2S, and G3S grafts had worse graft and overall survival at 90 days and 1-year (p <0.001). There was no difference in graft or overall survival of G1S or G3S grafts compared to G2S grafts until after adjustment in which G3S grafts were found to be associated with an increased risk of graft loss-aHR 1.27 (1.03-1.57), p = 0.02.
Discussion: Liver grafts can be categorized into three categories: (1) <20% or "very low risk", (2) 20-39% or "low-to-moderate risk", and usually acceptable, and (3) ≥40% steatosis or "moderate-to-high risk".
How to cite this article: Da BL, Satiya J, Heda RP, et al. Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S5-S14.
背景:移植物大脂肪变性可导致更高的移植物损失风险,因此我们试图重新定义移植物脂肪变性的可接受临界值。方法:利用UNOS-STAR数据库中2004年1月至2018年12月期间接受肝移植(LT)的26103例供体的数据。高风险脂肪变性(HRS)移植物和低风险脂肪变性(LRS)移植物的定义为≥20%。结果:LRS移植物在90天和1年的总生存率(93.3%和87.7%)和总生存率(95.4和90.5%)优异。与LRS移植相比,G1S、G2S和G3S移植在90天和1年的移植和总生存率较差(p p = 0.02)。讨论:肝移植可分为三类:(1)文章引用方式:Da BL, Satiya J, Heda RP, et al。脂肪变性肝移植后的结果:重新定义脂肪变性肝移植的可接受临界值。中华肝病与胃肠病杂志,2012;12(增刊1):559 - 564。
{"title":"Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts.","authors":"Ben L Da, Jinendra Satiya, Rajiv P Heda, Yu Jiang, Lawrence F Lau, Ahmed Fahmy, Aaron Winnick, Nitzan Roth, Elliot Grodstein, Paul J Thuluvath, Ashwani K Singal, Thomas D Schiano, Lewis W Teperman, Sanjaya K Satapathy","doi":"10.5005/jp-journals-10018-1361","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1361","url":null,"abstract":"<p><strong>Background: </strong>Graft macrosteatosis can predispose to a higher risk of graft loss so we sought to redefine acceptable cutoffs for graft steatosis.</p><p><strong>Methods: </strong>Data of 26,103 donors who underwent liver transplantation (LT) between January 2004 and December 2018 from the UNOS-STAR database were utilized. A high-risk steatotic (HRS) graft and a low-risk steatotic (LRS) graft were defined as ≥20% and <20% macrosteatosis, respectively. High-risk steatotic grafts were further classified as grafts with 20-29% (G1S grafts), 30-39% (G2S grafts), and ≥40% steatosis (G3S grafts). Outcomes between groups were compared.</p><p><strong>Results: </strong>LRS grafts had excellent graft (93.3 and 87.7%) and overall survival (95.4 and 90.5%) at 90 days and 1 year. Compared to LRS grafts, G1S, G2S, and G3S grafts had worse graft and overall survival at 90 days and 1-year (<i>p</i> <0.001). There was no difference in graft or overall survival of G1S or G3S grafts compared to G2S grafts until after adjustment in which G3S grafts were found to be associated with an increased risk of graft loss-aHR 1.27 (1.03-1.57), <i>p</i> = 0.02.</p><p><strong>Discussion: </strong>Liver grafts can be categorized into three categories: (1) <20% or \"very low risk\", (2) 20-39% or \"low-to-moderate risk\", and usually acceptable, and (3) ≥40% steatosis or \"moderate-to-high risk\".</p><p><strong>How to cite this article: </strong>Da BL, Satiya J, Heda RP, <i>et al</i>. Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S5-S14.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"12 Suppl 1","pages":"S5-S14"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/00/ejohg-12-s5.PMC9681573.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35253233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract The current decade has witnessed significant developments with the latest therapeutic agents for managing various infectious diseases to complex hemato-oncological conditions, leading to a decrease in morbidity and mortality, while improving the quality of life (QoL), and increasing the life span. Non-communicable diseases (NCDs), which are on the rise across all age-groups, are being driven by unhealthy lifestyles and improved mental health issues. The current therapeutic agents were found to offer only symptomatic relief of varying efficacy and significant adverse effects, leading clinicians to evaluate other options for the management of both neurodevelopmental and neurodegenerative disorders. The role of gut microbiota has emerged as a potential target for the treatment of both neurodegenerative diseases and neurodevelopmental disorders like attention-deficit hyperactivity disorder (ADHD)/autism spectrum disorders (ASD) as a result of the decoding of the human genome and advances in our understanding of the human gut microbiome, including its interactions with the human brain. This review has been undertaken to understand on date level of understanding of human microbiota and towards identifying probiotic strains with proven efficacy and safety. According to recent investigations, several lactobacillus strains, including L. Paracasei 37, L. Planetarium 128, L. reuteri DSM 17938, and Bifidobacterium longum, have been effective in treating children's neurodevelopmental disorders such as ASD and ADHD. Future clinical studies are nonetheless required to confirm the long-term safety and effectiveness of probiotic strains in managing the primary and comorbid symptoms, hence improving patient and family quality of life. How to cite this article Khanna HN, Roy S, Shaikh A, et al. Emerging Role and Place of Probiotics in the Management of Pediatric Neurodevelopmental Disorders. Euroasian J Hepato-Gastroenterol 2022;12(2):102–108.
{"title":"Emerging Role and Place of Probiotics in the Management of Pediatric Neurodevelopmental Disorders.","authors":"Himani Narula Khanna, Sushovan Roy, Aqsa Shaikh, Viswanath Bandi","doi":"10.5005/jp-journals-10018-1384","DOIUrl":"10.5005/jp-journals-10018-1384","url":null,"abstract":"Abstract The current decade has witnessed significant developments with the latest therapeutic agents for managing various infectious diseases to complex hemato-oncological conditions, leading to a decrease in morbidity and mortality, while improving the quality of life (QoL), and increasing the life span. Non-communicable diseases (NCDs), which are on the rise across all age-groups, are being driven by unhealthy lifestyles and improved mental health issues. The current therapeutic agents were found to offer only symptomatic relief of varying efficacy and significant adverse effects, leading clinicians to evaluate other options for the management of both neurodevelopmental and neurodegenerative disorders. The role of gut microbiota has emerged as a potential target for the treatment of both neurodegenerative diseases and neurodevelopmental disorders like attention-deficit hyperactivity disorder (ADHD)/autism spectrum disorders (ASD) as a result of the decoding of the human genome and advances in our understanding of the human gut microbiome, including its interactions with the human brain. This review has been undertaken to understand on date level of understanding of human microbiota and towards identifying probiotic strains with proven efficacy and safety. According to recent investigations, several lactobacillus strains, including L. Paracasei 37, L. Planetarium 128, L. reuteri DSM 17938, and Bifidobacterium longum, have been effective in treating children's neurodevelopmental disorders such as ASD and ADHD. Future clinical studies are nonetheless required to confirm the long-term safety and effectiveness of probiotic strains in managing the primary and comorbid symptoms, hence improving patient and family quality of life. How to cite this article Khanna HN, Roy S, Shaikh A, et al. Emerging Role and Place of Probiotics in the Management of Pediatric Neurodevelopmental Disorders. Euroasian J Hepato-Gastroenterol 2022;12(2):102–108.","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"12 2","pages":"102-108"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/71/93/ejohg-12-102.PMC10028704.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9171983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.5005/jp-journals-10018-1379
Zain Majid, Ghazi Abrar, Syed Mudassir Laeeq, Shoaib Ahmed Khan, Hina Ismail, Ghous Bux Soomro, Nasir Mehmood, Abbas Ali Tasneem, Farina Muhammad Hanif, Rajesh Mandhwani, Nasir Hasan Luck
Aim: Wilson's disease (WD) is a rare autosomal recessive disease, that can involve any organ of the body, the main ones being the liver and the brain. These patients can have varied presentations, ranging from having no symptoms to having neurological manifestations to features of chronic liver disease (CLD). Those patients that end up having CLD are prognosticated via the Child-Turcotte-Pugh (CTP) score and the Model for End-stage Liver Disease (MELD) score. However, two specific scores exist for prognostication in patients having WD, namely, the Nazar score and the Dhawan score. However, these are yet to be validated nor has their use been implemented in clinical practice.
Materials and methods: Our study involved 65 patients with WD, comprising both the pediatric and the adult population. We aimed at evaluating the clinical manifestations the lab parameters and the management of these patients. Furthermore, we tried validating the Nazar and the Dhawan score and later compared them with the CTP and the MELD score, which are well-known prognostic tools in CLD.
Results: Our patients were subdivided into the pediatric (more than 50%) and the adult group. The most common presenting complaint noted in both groups was abdominal distension. Values of the urine copper and serum ceruloplasmin did not defer between the pediatric and adult patients. Hepatic involvement is frequently seen in the pediatric age-group. Also, CTP class C was chiefly seen in pediatrics 17/33 (51.5%), while CTP class B was in adults 13/32 (40.6%). The mean Nazar score was 3 ± 3, while the mean Dhawan score was 5 ± 4. The main treatment offered for both groups was zinc along with penicillamine.
Conclusion: Our study showed the Dhawan score was comparable to the CTP and the MELD score in terms of predicting the disease severity of WD in our patient population.
How to cite this article: Majid Z, Abrar G, Laeeq SM, et al. Clinical Characteristics and Comparison of Different Prognostic Scores in Wilson's Disease. Euroasian J Hepato-Gastroenterol 2022;12(2):69-72.
{"title":"Clinical Characteristics and Comparison of Different Prognostic Scores in Wilson's Disease.","authors":"Zain Majid, Ghazi Abrar, Syed Mudassir Laeeq, Shoaib Ahmed Khan, Hina Ismail, Ghous Bux Soomro, Nasir Mehmood, Abbas Ali Tasneem, Farina Muhammad Hanif, Rajesh Mandhwani, Nasir Hasan Luck","doi":"10.5005/jp-journals-10018-1379","DOIUrl":"10.5005/jp-journals-10018-1379","url":null,"abstract":"<p><strong>Aim: </strong>Wilson's disease (WD) is a rare autosomal recessive disease, that can involve any organ of the body, the main ones being the liver and the brain. These patients can have varied presentations, ranging from having no symptoms to having neurological manifestations to features of chronic liver disease (CLD). Those patients that end up having CLD are prognosticated <i>via</i> the Child-Turcotte-Pugh (CTP) score and the Model for End-stage Liver Disease (MELD) score. However, two specific scores exist for prognostication in patients having WD, namely, the Nazar score and the Dhawan score. However, these are yet to be validated nor has their use been implemented in clinical practice.</p><p><strong>Materials and methods: </strong>Our study involved 65 patients with WD, comprising both the pediatric and the adult population. We aimed at evaluating the clinical manifestations the lab parameters and the management of these patients. Furthermore, we tried validating the Nazar and the Dhawan score and later compared them with the CTP and the MELD score, which are well-known prognostic tools in CLD.</p><p><strong>Results: </strong>Our patients were subdivided into the pediatric (more than 50%) and the adult group. The most common presenting complaint noted in both groups was abdominal distension. Values of the urine copper and serum ceruloplasmin did not defer between the pediatric and adult patients. Hepatic involvement is frequently seen in the pediatric age-group. Also, CTP class C was chiefly seen in pediatrics 17/33 (51.5%), while CTP class B was in adults 13/32 (40.6%). The mean Nazar score was 3 ± 3, while the mean Dhawan score was 5 ± 4. The main treatment offered for both groups was zinc along with penicillamine.</p><p><strong>Conclusion: </strong>Our study showed the Dhawan score was comparable to the CTP and the MELD score in terms of predicting the disease severity of WD in our patient population.</p><p><strong>How to cite this article: </strong>Majid Z, Abrar G, Laeeq SM, <i>et al</i>. Clinical Characteristics and Comparison of Different Prognostic Scores in Wilson's Disease. Euroasian J Hepato-Gastroenterol 2022;12(2):69-72.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"12 2","pages":"69-72"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/66/ejohg-12-69.PMC10028702.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9178897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-01DOI: 10.5005/jp-journals-10018-1381
Satyam Satyam, Kaustav Jain, Gaurav Pradhan
Background: Necrotizing colitis (NC) with perforation is a rare complication of the obstructive cancer of the right colon.
Case description: We report here a case of a 45-year-old female patient of mucinous adenocarcinoma of ascending colon, which presented as acute NC with perforation proximal to obstructing colonic carcinoma with their imaging features on computed tomography (CT). The purpose of this article is to highlight the role of CT in distinguishing an ischemic and a tumoral segment in the carcinomas complicated by proximal bowel ischemia.
Conclusion: Imaging plays a great role in distinguishing an ischemic and a tumoral segment in carcinomas complicated by proximal bowel ischemia. The identification of NC will help to accurately stage colonic cancer.
How to cite this article: Satyam S, Jain K, Pradhan G. Necrotizing Colitis with Perforation Proximal to Obstructive Ascending Colon Cancer: A Case Report. Euroasian J Hepato-Gastroenterol 2022;12(2):95-97.
{"title":"Necrotizing Colitis with Perforation Proximal to Obstructive Ascending Colon Cancer: A Case Report.","authors":"Satyam Satyam, Kaustav Jain, Gaurav Pradhan","doi":"10.5005/jp-journals-10018-1381","DOIUrl":"10.5005/jp-journals-10018-1381","url":null,"abstract":"<p><strong>Background: </strong>Necrotizing colitis (NC) with perforation is a rare complication of the obstructive cancer of the right colon.</p><p><strong>Case description: </strong>We report here a case of a 45-year-old female patient of mucinous adenocarcinoma of ascending colon, which presented as acute NC with perforation proximal to obstructing colonic carcinoma with their imaging features on computed tomography (CT). The purpose of this article is to highlight the role of CT in distinguishing an ischemic and a tumoral segment in the carcinomas complicated by proximal bowel ischemia.</p><p><strong>Conclusion: </strong>Imaging plays a great role in distinguishing an ischemic and a tumoral segment in carcinomas complicated by proximal bowel ischemia. The identification of NC will help to accurately stage colonic cancer.</p><p><strong>How to cite this article: </strong>Satyam S, Jain K, Pradhan G. Necrotizing Colitis with Perforation Proximal to Obstructive Ascending Colon Cancer: A Case Report. Euroasian J Hepato-Gastroenterol 2022;12(2):95-97.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"12 2","pages":"95-97"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/39/ejohg-12-95.PMC10028708.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9224492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Arteriovenous fistulas (AVF) of the superior mesenteric vasculature are rare vascular abnormalities. It often occurs due to iatrogenic injuries during bowel resection or abdominal traumas. As the patient exhibits a variety of signs and symptoms and can present late, diagnosis may be difficult.Multidetector computed tomography (MDCT) is the most common modality for imaging the small bowel, vessels, and mesentery in patients with mesenteric ischemia.
Case presentation: We present the case of a 25-year-old man who presented with features of acute intestinal obstruction and was operated on in an emergency. Resection of gangrenous small bowel and bowel adhesiolysis with double barrel ileostomy was performed. During exploratory laparotomy, gangrenous bowels were found, but no cause of mesenteric ischemia could be delineated. Finally, on computed tomography angiography (CTA) superior mesenteric arteriovenous fistula (SMAVF) with superior mesenteric vein (SMV) thrombosis was diagnosed. The patient was advised of aggressive anticoagulant therapy.
Conclusion: Computed tomography angiography has become the most reliable diagnostic modality to confirm the diagnosis and guide the best treatment strategy.
How to cite this article: Satyam S, Kose S, Singh S, et al. Multidetector Computed Tomography Angiography Role in Diagnosing Superior Mesenteric Arteriovenous Fistula with Superior Mesenteric Vein Thrombosis: A Case Report. Euroasian J Hepato-Gastroenterol 2022;12(2):98-101.
{"title":"Multidetector Computed Tomography Angiography Role in Diagnosing Superior Mesenteric Arteriovenous Fistula with Superior Mesenteric Vein Thrombosis: A Case Report.","authors":"Satyam Satyam, Snehal Kose, Sapna Singh, Anjali Prakash, Anju Garg","doi":"10.5005/jp-journals-10018-1380","DOIUrl":"10.5005/jp-journals-10018-1380","url":null,"abstract":"<p><strong>Introduction: </strong>Arteriovenous fistulas (AVF) of the superior mesenteric vasculature are rare vascular abnormalities. It often occurs due to iatrogenic injuries during bowel resection or abdominal traumas. As the patient exhibits a variety of signs and symptoms and can present late, diagnosis may be difficult.Multidetector computed tomography (MDCT) is the most common modality for imaging the small bowel, vessels, and mesentery in patients with mesenteric ischemia.</p><p><strong>Case presentation: </strong>We present the case of a 25-year-old man who presented with features of acute intestinal obstruction and was operated on in an emergency. Resection of gangrenous small bowel and bowel adhesiolysis with double barrel ileostomy was performed. During exploratory laparotomy, gangrenous bowels were found, but no cause of mesenteric ischemia could be delineated. Finally, on computed tomography angiography (CTA) superior mesenteric arteriovenous fistula (SMAVF) with superior mesenteric vein (SMV) thrombosis was diagnosed. The patient was advised of aggressive anticoagulant therapy.</p><p><strong>Conclusion: </strong>Computed tomography angiography has become the most reliable diagnostic modality to confirm the diagnosis and guide the best treatment strategy.</p><p><strong>How to cite this article: </strong>Satyam S, Kose S, Singh S, <i>et al</i>. Multidetector Computed Tomography Angiography Role in Diagnosing Superior Mesenteric Arteriovenous Fistula with Superior Mesenteric Vein Thrombosis: A Case Report. Euroasian J Hepato-Gastroenterol 2022;12(2):98-101.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"12 2","pages":"98-101"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/be/ejohg-12-98.PMC10028700.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9171977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}